Volume 3 / Issue 1
We are excited to present the Oncotype DX Breast Cancer Assay newsletter, filled with news and information from Genomic Health Inc.®, to keep you well informed and help you manage your patients with early-stage invasive breast cancer and ductal carcinoma in situ (DCIS).
A 2nd validation study for the Oncotype DX Breast Cancer Assay for DCIS unveiled at the 2014 San Antonio Breast Cancer Symposium
The Oncotype DX Breast Cancer Assay for DCIS is a tool to help physicians map out a personalized treatment plan for their patients. That news is spreading rapidly. Recently, at the 2014 San Antonio Breast Cancer Symposium, Dr. Eileen Rakovitch presented the second validation study for the Oncotype DX Breast Cancer Assay for DCIS. Since that time, several articles have focused on the newly reported study and how the breast cancer assay for DCIS is helping providers and patients discuss their treatment options. Please check out a video and article from The ASCO Post to learn what all the buzz is about
<strong>Spotlight on - A Patient’s Perspective: Joan Lunden, <em>Good Morning America</em></strong>
<strong>The Days of “One Size Fits All” are Gone</strong>
Joan Lunden presented the keynote address to a packed audience at the Miami Breast Cancer Conference on February 27th, 2015. “I am here today to put a face on the patients you see every day—to paint a picture of their experience.”
The 32nd Miami Breast Cancer Conference February 26 – March 1 opened doors for a more personalized approach to breast cancer patient care with presentations that included assessing the risk of recurrence and the benefits of various treatment regimens.
Copyright © 2004-2017 Genomic Health, Inc. All Rights Reserved.
The content on this site is intended for U.S. patients and caregivers only.